Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Loredana Bianchi
Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation
OncoTargets and Therapy
Oncology
Pharmacology
Related publications
Reply: Capecitabine and Bevacizumab as First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-Ras Mutation Status: Analysis of a Phase III Study of Bevacizumab With Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Oncologist
Cancer Research
Medicine
Oncology
Correction: A Phase II Trial of 1st-Line Modified-Folfoxiri Plus Bevacizumab Treatment for Metastatic Colorectal Cancer Harboring RAS Mutation: JACCRO CC-11
Oncotarget
Oncology
Cetuximab in First Line Treatment of Metastatic Colorectal Cancer
Farmeconomia. Health economics and therapeutic pathways
Discontinuation of First-Line Bevacizumab in Metastatic Colorectal Cancer: The BEAWARE Italian Observational Study
Tumori
Medicine
Cancer Research
Oncology
Bevacizumab in First-Line Treatment of Elderly Patients With Metastatic Colorectal Cancer: German Community-Based Observational Cohort Study Results
BMC Cancer
Cancer Research
Oncology
Genetics
Impact of Tumour RAS/BRAF Status in a First-Line Study of Panitumumab + FOLFIRI in Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
The Addition of Bevacizumab in the First-Line Treatment for Metastatic Colorectal Cancer: An Updated Meta-Analysis of Randomized Trials
Oncotarget
Oncology
Critical Appraisal of Bevacizumab in the Treatment of Metastatic Colorectal Cancer
OncoTargets and Therapy
Oncology
Pharmacology
